Shimoli Barot discusses how OPTIMA may change treatment decisions
— Shimoli Barot discusses how OPTIMA may change treatment decisions
by Gregory Laub, Senior Director, Video, MedPage Today
July 1, 2026
• 3 min read
At the American Society of Clinical Oncology (ASCO) meeting, results from the OPTIMA trial suggested that genomic testing may help identify additional patients with hormone receptor-positive/HER2-negative early breast cancer who can safely avoid adjuvant chemotherapy.
Experts discuss Prosigna-guided treatment decisions in high-risk early disease
CHICAGO — In this video, Shimoli Barot, MD, discusses a study that showed a genomic test could be used to identify patients with…
As many as 5,000 women a year with hormone-sensitive breast cancer could benefit
Un ensayo clínico con miles de participantes cambió lo que se sabía sobre un tratamiento habitual.Los resultados sorprendieron…
A large-scale international study has found that an advanced genomic test can identify which breast cancer patients can avoid…
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
